Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,522.00
(
0.33%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,608.61
(
0.33%
)
News Focus
News Focus
Post# of 257660
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123038
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: spongepaul post# 211353

Tuesday, 05/16/2017 7:04:28 PM

Tuesday, May 16, 2017 7:04:28 PM

Post# of 257660
(CHRS/MNTA/AMGN/etc)—Re: ABBV’s ‘135 Humira patent invalidated

This is bullish for all companies seeking to commercialize Humira FoBs for the US market (as noted in #msg-131355570).

Had ABBV’s ‘135 patent been upheld (or should ABBV prevail on appeal to the CAFC, which is very unlikely, IMO), then Humira-FoB labels would have excluded biweekly subcutaneous dosing to treat RA, which is Humira’s largest single indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today